Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Pantoprazole does not reduce upper gastrointestinal bleeding during anticoagulation treatment

07 Aug 2019

Proton pump inhibitor therapy, particularly with pantoprazole, does not reduce upper gastrointestinal bleeding events in patients taking low-dose anticoagulation/aspirin treatment, reports a recent study.

Researchers randomly assigned 17,598 patients with stable cardiovascular and peripheral artery disease to receive either daily 40-mg pantoprazole (n=8,791; mean age, 67.6±8.1 years; 22 percent female) or placebo (n=8,807; mean age, 67.7±8.1 years; 21 percent female). Participants were also given rivaroxaban 2.5 mg twice daily with 100-mg aspirin once daily, rivaroxaban 5 mg twice daily or aspirin 100 mg alone.

The primary efficacy outcome of clinically significant events in the upper gastrointestinal tract occurred in 1.2 percent (n=102) of the pantoprazole arm and in 1.3 percent (n=116) of the placebo group. The difference did not reach significance (hazard ratio [HR], 0.88, 95 percent CI, 0.67–1.15).

Further analysis according to the components of upper gastrointestinal bleeding showed that both treatment arms were comparable in terms of overt or occult bleeding events. However, the likelihood of gastroduodenal bleeding was significantly attenuated in patients who were given pantoprazole (HR, 0.52, 0.28–0.94; p=0.03).

In a subsequent posthoc analysis where the definition of bleeding events was broadened, pantoprazole use remained significantly associated with a lower risk of bleeding of gastroduodenal lesions (HR, 0.45, 0.27–0.74). Pantoprazole also exerted a significant protective effect against peptic ulcer (HR, 0.46, 0.25–0.83) and erosions (HR, 0.13–0.84).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.